For years, artificial intelligence has been pitched as a way to speed up one of the slowest, most expensive parts of medicine: finding new drugs. Now the industry is reaching a more revealing stage — checking whether medicines dreamed up with the help of AI actually work in people.
According to BioPharma Dive, which examined the question in a recent analysis, the key issue is how well AI-discovered drugs are faring in the clinic. That framing matters because designing a promising molecule on a computer is very different from proving it is safe and effective in human trials, where the vast majority of experimental drugs ultimately fail.
The distinction is worth keeping in mind as AI-driven biotech attracts attention and investment. A compound identified or optimized by machine-learning tools still has to move through the same phased clinical trials as any conventional drug, facing the same regulators and the same biological unknowns. Early clinical results are the first hard evidence of whether AI's speed advantage in the lab translates into better odds later on.
BioPharma Dive's coverage centers on that reality check: separating the marketing around AI drug discovery from what the trial data so far can actually support.
Why it matters: if AI-designed medicines can clear clinical trials at rates comparable to — or better than — traditionally discovered drugs, it would validate a technology many companies are betting billions on to make new treatments faster and cheaper.